Bildnachweis: ITM. The radiopharmaceutical industry is entering a new era. Driven by clinical breakthroughs, regulatory ...

BWX Technologies reached a record high, leading nuclear-related stocks on reports the US Secretary of Transportation is set ...

(ST. JOSEPH, Mo) Mosaic Life Care is advancing its cancer treatment for patients with metastatic prostate cancer. PLUVICTO is ...

Average selling prices of Illuccix will likely decrease when its transitional pass-through payment status expires in 2025.

The neuroendocrine prostate cancer treatment space will experience significant changes during the forecast period of 2025–2034, owing to the launch of novel therapies such as BXCL701, Peluntamig, ...

Pluvicto (lutetium-177 vipivotide tetraxetan) is a radioligand therapy that targets the PSMA protein on prostate cancer cells ...

Navigating a metastatic castration-resistant prostate cancer (mCRPC) diagnosis while preserving self-identity can feel like ...

Telix Pharmaceuticals' strong sales, diverse pipeline, and theranostics promise support a Buy rating, despite SEC concerns.

Led by former Novartis executive Emanuele Ostuni, the startup has a prostate cancer medicine advancing into early clinical ...

Patients on Itovebi plus Ibrance and fulvestrant had improved progression-free and overall survival compared to Ibrance-fulvestrant alone.

Q2 2025 Earnings Call Transcript July 21, 2025 Operator: Good morning and good afternoon, and welcome to the Novartis Q2 2025 Results Release Conference Call and Live Webcast. [Operator Instructions].